Can we target insulin signalling for cognition therapeutics?

Simone Macrì Giovanni Laviola Centre for Behavioural Sciences and Mental Health,Istituto Superiore di Sanità (ISS),Rome,Italy
DOI: https://doi.org/10.1080/14728222.2024.2407821
IF: 6.797
2024-09-26
Expert Opinion on Therapeutic Targets
Abstract:KEYWORDS: While the role of insulin in glucose homeostasis and energy metabolism has been known for over a century, its role in cognition and higher-order brain functions has emerged much more recently [ Citation 1 ]. Specifically, impairments in insulin signaling are now being associated with cognitive impairments at large, spanning from attentional to memory deficits and then onto perseveration and behavioral inflexibility. A recent systematic review reported a strong association between insulin-related metabolic disorders (e.g., type 2 diabetes, metabolic syndrome, and obesity) and impairments in verbal and numerical reasoning, and processing speed (see table 2 in reference [ Citation 2 ]). Similarly, a systematic review of mouse and rat studies investigating the role of impaired insulin signaling on cognition revealed that a hyperglycemic trait in rodents resulted in impaired cognition in approximately 90% of instances (see table 1 in reference [ Citation 3 ]). At a clinical level, a strong association between Alzheimer's disease (AD) and insulin resistance (IR) has also been observed [ Citation 4 ].
pharmacology & pharmacy
What problem does this paper attempt to address?